Quest Diagnostics Stock - Consensus and analyst view on the testing specialist
19.06.2026 - 20:18:56 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/19/2026, 18:18 UTC. Details in the imprint.
Quest Diagnostics (US74834L1008) remains a core US diagnostic testing provider with stable cash flows and broad index membership. With no major new filings or press releases emerging today, Wall Street's consensus on the stock moves to center stage for investors.
All news and data on Quest Diagnostics stock
Key company announcements, filings and quote data for Quest Diagnostics are aggregated on the ad hoc news topic page and the company's own investor-relations site.
What recent filings show
Quest Diagnostics last reported quarterly results for the first quarter of 2026 in late April, confirming continued demand for routine lab testing and esoteric diagnostics. Management reiterated its focus on cost discipline and network efficiency in that update.
According to the company's filings, revenue remains well diversified across routine testing, advanced diagnostics and health plan contracts, limiting dependence on any single payer group. Cash generation has historically supported dividends and share repurchases.
How analysts rate the stock
Data compiled on major financial portals shows that Wall Street maintains a largely neutral stance on Quest Diagnostics stock, with a broad mix of Hold and Buy recommendations. Only a small minority of analysts rate the shares at Underperform or Sell.
The consensus 12-month price target clusters moderately above the recent share price, indicating expectations for modest upside rather than a strong re-rating. Earnings-per-share estimates for 2026 and 2027 imply only low-single-digit growth, reflecting a mature, defensive business profile.
Where consensus sees earnings
Consensus forecasts point to relatively stable margins over the next two years, helped by automation in laboratories and ongoing procurement savings. However, analysts also flag reimbursement pressure from public payers as a limiting factor for more robust profit growth.
Volume trends in routine testing are expected to track overall healthcare utilization in the US, rather than delivering outsized expansion. On balance, this positions Quest Diagnostics stock as a defensive healthcare holding rather than a high-growth story in most research models.
How Quest Diagnostics makes money
Quest Diagnostics generates most of its revenue by providing diagnostic information services, including routine blood tests, specialized oncology and genetic testing, and health screening programs for physicians, hospitals, employers and health plans across the United States.
Where the stock trades today
Quest Diagnostics shares (US74834L1008) trade on the New York Stock Exchange at $140.25 as of 06/19/2026, 16:00 ET.
Key facts on Quest Diagnostics stock
- Company: Quest Diagnostics Inc.
- ISIN: US74834L1008
- WKN: 916895
- Ticker: DGX
- Venue: NYSE
- Price (as of 06/19/2026, 16:00 ET): 140.25 USD
- Market cap: 15,800,000,000 USD (as of 06/19/2026)
- Sector / Industry: Health Care / Diagnostics & Research
- Index membership: Standard & Poor's 500 index
- Next earnings date: 07/23/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
